Article
In this segment, Dr. Susan Urba, University of Michigan, Comprehensive Cancer Center, talks about treatment guidelines and decisions relevant to chemotherapy-induced nausea and vomiting (CINV) in a managed care setting.
In addition, Dr. Urba warns of the consequences associated with the treatment of CINV when cost concerns impact best practices. Often, these consequences can include increased costs from uncontrolled symptoms and potential hospital admission due to dehydration.
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.